Brain-Only Versus GI-Only Synucleinopathy: A Comprehensive Autopsy Study With Both IHC and SAA

This comprehensive autopsy study utilizing both immunohistochemistry and RT-QuIC seed amplification assays on 50 Parkinson's disease and 128 control subjects suggests that brain-only synucleinopathy is approximately 16 times more common than GI-only synucleinopathy, while also demonstrating that the burden of alpha-synuclein in the gastrointestinal tract correlates significantly with motor and autonomic dysfunction.

The Gist

The Big Question: Where Does Parkinson's Start?

For a long time, scientists have been debating a "chicken or the egg" mystery regarding Parkinson's disease.

• The "Brain-First" Theory: The disease starts in the brain and slowly spreads down to the body.
• The "Body-First" Theory (specifically the Gut-First theory): The disease starts in the digestive system (the gut), travels up the vagus nerve (like a biological internet cable), and eventually invades the brain.

This new study set out to solve this mystery by looking at the bodies of 178 people after they passed away. They wanted to see if they could find people who had the "Parkinson's protein" (called alpha-synuclein) only in their gut, or only in their brain.

The Detective Work: Two Different Flashlights

To find this protein, the researchers used two different "flashlights" (detection methods):

1. IHC (Immunohistochemistry): This is like a standard flashlight. It's good, but sometimes it misses faint clues. It looks for the protein under a microscope.
2. SAA (Seed Amplification Assay): This is like a high-tech, super-sensitive night-vision camera with a magnifying glass. It can detect tiny, invisible seeds of the protein that the standard flashlight misses. The researchers used this new, super-sensitive tool on 10 different parts of the digestive tract for every single person.

The Investigation Results

The researchers looked at three groups of people:

1. Parkinson's Patients: People who definitely had the disease.
2. ILBD (Incidental Lewy Body Disease): People who had the protein in their brains but never showed symptoms while alive.
3. NLB (No Lewy Bodies): Healthy controls with no signs of the disease.

Here is what they found:

1. The "Gut-Only" Mystery (The Rare Unicorn)
The researchers hoped to find people who had the protein only in their gut and not in their brain. This would prove the "Gut-First" theory.

• The Result: They found only 2 people out of 178 who fit this description.
• The Catch: Even in these two people, the protein was found in very few places in the gut (one person had it in just the rectum; the other in 6 places). It was extremely rare.

2. The "Brain-Only" Reality (The Common Occurrence)
They then looked for people who had the protein only in the brain and not in the gut.

• The Result: They found 11 people who had it in the brain but not the gut.
• The Estimate: Because they only checked a few brain spots initially, they estimated that if they checked every brain spot on everyone, there would likely be about 32 people with "Brain-Only" disease.

The Verdict:
The study suggests that "Brain-Only" cases are about 16 times more common than "Gut-Only" cases.

What Does This Mean? (The Analogy)

Imagine the brain and the gut are two houses connected by a long hallway (the vagus nerve).

• The Old Theory: Someone thought the "fire" (the disease) always started in the kitchen (the gut) and spread to the living room (the brain).
• This Study's Finding: The researchers found that in almost every case, the fire started in the living room (the brain) and only later spread to the kitchen.
• The Exception: They did find two houses where the fire seemed to be only in the kitchen, but these were so rare (1 in 16) that they are likely just a weird exception, not the rule.

The Connection to Symptoms

Even though the disease usually starts in the brain, the study found a strong link between the amount of "bad protein" in the gut and how sick the person felt.

• The Analogy: Think of the protein in the gut like "rust" on a machine. The more rust you find in the gut, the more likely the person was to have:
  • Constipation (trouble moving the machine).
  • Excessive drooling.
  • Tremors and stiffness.

So, even if the disease started in the brain, the damage it does to the gut is a major cause of the uncomfortable symptoms patients feel.

The Bottom Line

This study challenges the popular idea that Parkinson's almost always starts in the gut. Instead, it suggests that for the vast majority of people, Parkinson's begins in the brain and eventually spreads to the body.

While a tiny handful of people might have a "Gut-First" version, the "Brain-First" version is the dominant story. This is a huge clue for doctors: if we want to stop Parkinson's before it destroys the brain, we might need to look at the brain much earlier than we thought, rather than just focusing on the gut.

Technical Summary

1. Problem Statement

The study addresses a central debate in Parkinson's disease (PD) etiology: the "body-first" versus "brain-first" hypothesis.

• The Hypothesis: Proposed by Braak and others, the "body-first" hypothesis suggests that PD pathology (Lewy body pathology or LBP) originates in the gastrointestinal (GI) tract (potentially via toxin absorption or microbial stimuli) and spreads to the central nervous system (CNS) via the vagus nerve.
• The Gap: While theoretical models (e.g., by Borghammer et al.) propose distinct "brain-first" and "body-first" subtypes of PD, empirical autopsy evidence for isolated GI synucleinopathy (pathology present in the GI tract but absent in the brain) has been scarce. Previous studies using immunohistochemistry (IHC) found that peripheral synuclein pathology rarely exists without concurrent brain pathology.
• The Challenge: Existing IHC methods may lack the sensitivity to detect early-stage synuclein seeds in the periphery. Furthermore, sparse sampling of the GI tract in previous studies may have missed isolated cases.

2. Methodology

The researchers conducted a comprehensive autopsy study utilizing two detection methods: standard Immunohistochemistry (IHC) and the highly sensitive RT-QuIC (Real-Time Quaking-Induced Conversion) Seed Amplification Assay (SAA).

• Cohort: 178 elderly subjects from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and the Brain and Body Donation Program (BBDP).
  • PD Group: 50 subjects with clinicopathologically confirmed PD.
  • ILBD Group: 34 subjects with Incidental Lewy Body Disease (brain IHC-positive, but clinically non-demented and without parkinsonism).
  • NLB Group: 94 subjects with no dementia, no parkinsonism, and no brain LBP detected by standard IHC.
• Sampling:
  • GI Tract: 10 distinct sites were sampled per subject: submandibular gland, upper/lower esophagus, stomach, duodenum, jejunum, ileum, transverse colon, sigmoid colon, and rectum.
  • Brain: Standard 10-region IHC assessment was performed. A subset of subjects underwent SAA on 4 critical brain regions (olfactory bulb, medulla, pons, amygdala).
• Detection Techniques:
  • IHC: Used antibodies specific for phosphorylated alpha-synuclein (pSyn) with proteinase K pretreatment to identify pathological aggregates.
  • RT-QuIC (SAA): A biochemical assay using mutant alpha-synuclein monomers to detect and amplify minute amounts of alpha-synuclein seeds (aggregates) in tissue homogenates. This method is significantly more sensitive than IHC.
• Study Design (Stepwise Approach):
  1. Screen all NLB subjects for GI SAA positivity.
  2. Repeat SAA on positive cases to confirm.
  3. Perform brain SAA on confirmed "GI-only" candidates to rule out occult brain pathology.
  4. Perform pSyn IHC on the GI tracts of SAA-positive NLB subjects to compare sensitivity.

3. Key Contributions

• Methodological Advancement: This is one of the first large-scale studies to apply RT-QuIC SAA to a comprehensive panel of 10 GI sites, moving beyond the limited sampling of previous studies.
• Comparative Sensitivity: The study directly compares the sensitivity of SAA versus IHC for detecting peripheral synucleinopathy.
• Quantitative Correlation: It establishes a statistical link between the burden of GI synuclein seeds (number of positive sites) and clinical motor/autonomic symptoms.
• Etiological Insight: It provides empirical data to test the "body-first" hypothesis, challenging the existence of a distinct "GI-only" PD subtype.

4. Results

• Prevalence of GI-Only Synucleinopathy:
  • Initial SAA screening of 94 NLB subjects identified 11 potential "GI-only" cases.
  • After repeat testing and subsequent brain SAA on these candidates, only 2 subjects were confirmed to have synucleinopathy restricted strictly to the GI tract (one positive in the rectum, one in 6 sites including esophagus and stomach).
  • Both confirmed GI-only subjects were clinically normal (no dementia or parkinsonism).
• Prevalence of Brain-Only Synucleinopathy:
  • Among the 94 NLB subjects, 11 were found to have synuclein pathology restricted to the brain (detected by SAA in brain regions despite negative GI SAA).
  • Based on proportional results, the authors estimate that if brain SAA were performed on all NLB subjects, an additional 21 "brain-only" cases would be identified, totaling ~32 brain-only cases.
  • Conclusion on Ratio: Brain-only LBP is estimated to be 16 times more common than GI-only LBP (32 vs. 2).
• Sensitivity Comparison (SAA vs. IHC):
  • SAA is significantly more sensitive than IHC. In the ILBD group, 71% (24/34) were GI SAA-positive, whereas only 41% (14/34) were GI IHC-positive.
  • In the NLB group, IHC found almost no specific GI pathology, while SAA detected seeds in 11 subjects.
• Clinical Correlations:
  • The number of SAA-positive GI sites per subject strongly correlated with the total brain pSyn burden (Spearman rho = 0.89).
  • GI SAA positivity correlated significantly with UPDRS motor scores and specific SCOPA-AUT GI symptoms (excess salivation, straining, constipation, and bowel movement frequency).
• Regional Gradient:
  • A rostrocaudal gradient was observed, with higher positivity rates in the upper GI tract (submandibular gland, esophagus, stomach) compared to the lower tract.

5. Significance and Conclusion

• Refutation of "Body-First" Dominance: The study provides little empirical support for the existence of a distinct "body-first" subtype of PD where pathology originates in the GI tract and spreads to the brain. Instead, the data suggests that in the vast majority of cases, synuclein pathology likely begins in the brain and spreads to the periphery.
• Nature of GI Pathology: The presence of alpha-synuclein seeds in the GI tract of clinically normal subjects (NLB) suggests that GI synucleinopathy may be a common age-related phenomenon or a secondary consequence of brain pathology, rather than the primary driver of PD.
• Diagnostic Implications: While SAA is a powerful tool for detecting early seeds, a positive GI SAA result does not necessarily equate to a "body-first" PD diagnosis, as these seeds often coexist with brain pathology or may represent non-pathogenic aggregates.
• Future Directions: The authors note that the 2 confirmed "GI-only" cases might represent preclinical cases of pure autonomic failure rather than PD, highlighting the need for further longitudinal studies to determine the clinical trajectory of isolated peripheral synucleinopathy.

In summary, this comprehensive autopsy study utilizing high-sensitivity SAA techniques suggests that brain-onset synucleinopathy is far more prevalent than GI-onset pathology, challenging the prevailing "body-first" hypothesis for the majority of Parkinson's disease cases.